577 filings
Page 3 of 29
6-K
9s9p1ge1i
6 Jan 23
Current report (foreign)
4:49pm
6-K
149jwm
30 Nov 22
Current report (foreign)
9:08pm
6-K
wcjte5rkzg5 ubld
29 Nov 22
Current report (foreign)
4:58pm
6-K
0u6fh uyywc
15 Nov 22
Current report (foreign)
4:43pm
6-K
z7ne0vq
9 Nov 22
Portage Biotech Announces Clinical Trial Collaboration Agreement with Merck
4:01pm
6-K/A
3k0de96tgea x89l
12 Oct 22
Financial Statements for the years ended Report of Independent Registered Public Accounting Firm
5:45pm
6-K
z8q65 ye8f
7 Oct 22
Notice of Annual General Meeting
3:06pm
6-K
1igj98sfs6f61lky
22 Sep 22
Current report (foreign)
4:07pm
6-K
6d1 iv18f5u
14 Sep 22
Current report (foreign)
10:31am
6-K
cgf4fkewkw0 tx2unism
29 Aug 22
Current report (foreign)
4:00pm
6-K
apnjx 78dulcbnakhkc9
19 Aug 22
Current report (foreign)
10:54am
424B5
in8nf7xw7pj6x6ov
19 Aug 22
Prospectus supplement for primary offering
10:52am
6-K
i7cg2jdp
1 Aug 22
Current report (foreign)
4:48pm
D
8fo1jnpuyh6onjlav
29 Jul 22
$34.64M in equity, sold $34.64M, 4 investors
6:15pm
6-K
5svr2pdza4biyz1q
19 Jul 22
Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform
9:01am
6-K
dnq8g 0ak
8 Jul 22
Current report (foreign)
8:58am
6-K
gn6nn
7 Jul 22
Portage Biotech Bolsters Pipeline with Acquisition of Four Candidates Targeting the Adenosine Pathway
8:30am
6-K
h863hmm aw4jv85rz
23 Jun 22
Territory of the British Virgin Islands
4:05pm
6-K
sfbka9 cvpcgk8
31 Mar 22
Portage Biotech Provides Update on Clinical-Stage and Development Programs
8:00am